{"id":"ttyp01-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TTYP01 tablets work by inhibiting the SARS-CoV-2 main protease, which is essential for the replication of the virus. This inhibition prevents the virus from replicating and reduces the severity of COVID-19 symptoms.","oneSentence":"TTYP01 tablets are a small molecule drug that targets the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:07.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT07252440","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease","status":"RECRUITING","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2025-12-05","conditions":"AD, Early Alzheimer's Disease","enrollment":180},{"nctId":"NCT06757504","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD","status":"RECRUITING","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2025-01-13","conditions":"Autism Spectrum Disorder (ASD)","enrollment":150},{"nctId":"NCT06648304","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-04-25","conditions":"Acute Ischemic Stroke","enrollment":614},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":"Healthy Adult Subjects","enrollment":72},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":"Healthy Adult Subjects","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TTYP01 tablets","genericName":"TTYP01 tablets","companyName":"Shanghai Auzone Biological Technology Co., Ltd.","companyId":"shanghai-auzone-biological-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TTYP01 tablets are a small molecule drug that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}